SCHEMBL3877412

SCHEMBL3877412

CCN(CC)C(=O)c1cccc(CNS(=O)(=O)c2ccc(-c3ccc(C#N)cc3)cc2)c1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.62
LMNA P02545 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HPGD P15428 2/20 0.53
HTT P42858 1/20 0.53
HSD11B1 P28845 5/20 0.51
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
OPRK1 P41145 1/20 0.47
KAT6A Q92794 1/20 0.46
LSS P48449 1/20 0.45
NAMPT P43490 1/20 0.45
KCNA5 P22460 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3877107 0.88 HPGD (0.60) CYP19A1LMNASMN1; SMN2HPGDHTT
SCHEMBL3873213 0.85 CYP19A1 (0.70) CYP19A1OPRK1KAT6ANAMPTPOLB
SCHEMBL3875005 0.84 CYP19A1 (0.66) CYP19A1LMNAHPGDMAPTOPRK1
SCHEMBL3875065 0.84 HPGD (0.69) CYP19A1LMNASMN1; SMN2HPGDHTT
SCHEMBL3873566 0.84 HSD11B1 (0.63) CYP19A1LMNASMN1; SMN2HPGDHTT
SCHEMBL3883798 0.83 HSD11B1 (0.65) CYP19A1LMNASMN1; SMN2HPGDHTT
SCHEMBL3884161 0.81 CYP19A1 (0.67) CYP19A1LMNASMN1; SMN2HPGDHTT
SCHEMBL3872241 0.80 LMNA (0.58) CYP19A1LMNASMN1; SMN2HPGDHTT
SCHEMBL3876577 0.80 CYP19A1 (0.67) CYP19A1LMNASMN1; SMN2HPGDHTT
SCHEMBL3940044 0.79 LMNA (0.57) CYP19A1LMNASMN1; SMN2HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 CYP19A1 23/4885LMNA 2473/4885SMN1; SMN2 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.